Episodios

  • More Than Babysitting: The Power of Type One Together with Raquel Baron

    More Than Babysitting: The Power of Type One Together with Raquel Baron
    Apr 10 2026

    Today on Diabetes Connections.. a bonus episode all about finding support and community online and in real life. Seems to be a theme lately and I could NOT be happier. Type One Together started with one college student, a few babysitting jobs, and a realization that there was a need.

    Type One Together has become something much bigger – they'll still help you find a sitter but they're also a hub for T1D info, support and gatherings. I'm talking to the founder, Raquel Baron, about how they got there, what kind of help they provide and what's next.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    More about Type One Together's events here - use promo code "connections" to save

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    32 m
  • In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!

    In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!
    Apr 7 2026

    It's In the News, a look at the top headlines and stories in the diabetes community.

    This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode!

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Stacey mentioned these two groups:

    Grownup T1Ds

    T1D to 100


    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    14 m
  • Grownup T1Ds: The Missing Support for Adults Living with Diabetes

    Grownup T1Ds: The Missing Support for Adults Living with Diabetes
    Mar 31 2026

    There's a reason we don't call it juvenile diabetes anymore. We all know you grow up and T1D doesn't go anywhere, and that you can be diagnosed at any age. But it often feels like adults are forgotten.

    I hope that's not the case here—but I hear it all the time in the broader community.

    Kelly Dawes is working to change that. She's started GrownUp T1Ds, a community built specifically for adults who've been living with type 1 for years and are finally finding connection, understanding, and support in a way they may never have had before.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    More about Grownup T1Ds here

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    37 m
  • In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more

    In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
    Mar 24 2026
    It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it. https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests XX Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX ...
    Más Menos
    11 m
  • Are We Finally Taking Mental Health Seriously in Diabetes Care?

    Are We Finally Taking Mental Health Seriously in Diabetes Care?
    Mar 17 2026

    We all know how important mental health is but unless you are VERY lucky, you're on your own.

    There are the rare programs out there for pediatric endocrinology and we've got one of the best Dr. Taylor Stephens is a pediatric psychologist with the Cleveland Clinic who specializes in pediatric endocrinology conditions. She's here to share what we can all do, right after diagnosis, and years later to support our kids and ourselves, if you're a caregiver or an adult living with type 1

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Learn more about the Mental Health + Diabetes Conference here. Use promo code "dmhconnections" to save 15% off your ticket

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    43 m
  • BONUS Episode: Dexcom Updates From ATTD with Jessica Castle, VP of Medical Affairs

    BONUS Episode: Dexcom Updates From ATTD with Jessica Castle, VP of Medical Affairs
    Mar 15 2026

    Bonus episode! I had the opportunity to talk to the folks at Dexcom about their presentations at ATTD and I wanted to bring you the interview sooner rather than later.

    ATTD is the Advanced Technology and Treatments for Diabetes conference, this year it took place in Barcelona. If you're new around here, there are a few big diabetes conferences where studies are presented and news is made. ATTD in spring, ADA and ADCES in summer and a few more scattered here and there.

    We'll be sharing more from ATTD in upcoming interviews with other tech companies. But today I'm talking to Jessica Castle, VP of Medical Affairs at Dexcom – she's also an adult endocrinologist with a lot of clinical trial experience.

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    28 m
  • In the News… $3 Semaglutide?, New Stem Cell Partnership, "Lyla's Law" Debate, Patient-Led Insulin Dosing in Pregnancy, FDA GLP-1 Crackdown, and more!

    In the News… $3 Semaglutide?, New Stem Cell Partnership, "Lyla's Law" Debate, Patient-Led Insulin Dosing in Pregnancy, FDA GLP-1 Crackdown, and more!
    Mar 10 2026
    It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost ...
    Más Menos
    12 m
  • Fixing the Most Overlooked Problem in Diabetes: Your Skin

    Fixing the Most Overlooked Problem in Diabetes: Your Skin
    Mar 3 2026

    Why don't we talk about our skin more?!

    When you or your child is diagnosed with diabetes, you quickly realize the skin is in for a rough time. Endless pokes from needles, infusion sets, CGM wires. You make it work, but what if there was a better way?

    I'm talking Marie Schiller and Kent Manson – they've teamed up to help with a solution now and one they're working on for the future. The available now treatment is Site Hero – a recovery patch to help sites heal.. and – for the future - a way to scan an area and help identify better injection or infusion sites at home. This is a great and practical conversation.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    Learn more about Site Hero and Healthy Sites here

    Announcing Community Commericals! Learn how to get your message on the show here.

    Learn more about studies and research at Thrivable here

    Please visit our Sponsors & Partners - they help make the show possible!

    Omnipod - Simplify Life

    All about Dexcom

    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    42 m